CN105213337A - Albendazole dispersible tablet for animals and preparation method thereof - Google Patents
Albendazole dispersible tablet for animals and preparation method thereof Download PDFInfo
- Publication number
- CN105213337A CN105213337A CN201510666691.3A CN201510666691A CN105213337A CN 105213337 A CN105213337 A CN 105213337A CN 201510666691 A CN201510666691 A CN 201510666691A CN 105213337 A CN105213337 A CN 105213337A
- Authority
- CN
- China
- Prior art keywords
- albendazole
- dispersible tablet
- major ingredient
- binding agent
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of albendazole dispersible tablet for animals, the ratio being 40 ~ 85:3 ~ 10:5 ~ 15:5 ~ 25 by ratio of weight and the number of copies by major ingredient, disintegrating agent, binding agent and adjuvant forms; Major ingredient is made up of one or more in nitroclofene, the two dichloro of sulfur, ipecine, triclabendazole, metronidazole, praziquantel and albendazole, adjuvant by micropowder silica gel, sodium lauryl sulphate one or both form.A preparation method for albendazole dispersible tablet for animals, carries out (1) weighing (2) according to the following steps and mills: symmetrical measured major ingredient carries out micronization processes, for subsequent use; (3) mix: the major ingredient of micronized process is mixed with disintegrating agent, binding agent and adjuvant, then carries out tabletting, obtain albendazole dispersible tablet.A kind of albendazole dispersible tablet for animals of the present invention and preparation method thereof, the dispersible tablet prepared is convenient to animal and is taken, and growth of animal is normal, can not cause too drastic stress to animal.
Description
Technical field
The invention belongs to animal anthelmintic technical field, specifically, relate to a kind of albendazole dispersible tablet for animals and preparation method thereof.
Background technology
Albendazole is the broad-spectrum de-worming medicine of a high-efficiency low-toxicity, within 1972, found by the animal health laboratory of GlaxoSmithKline PLC company, albendazole in vivo metabolism is after sulfoxide type or sulfone class, suppress parasite to the absorption of glucose, cause polypide glycogen depletion, or suppress fumaric reductase system, hinder the generation of ATP, parasite cannot be survived and breed.For high-efficiency broad spectrum anthelmintic new drug, be that in benzimidazole class medicine, anthelmintic spectrum is comparatively wide, the one that insecticidal action is the strongest.All there is high activity to nematicide, schistosomicide, cestode, and to ovulation development, there is remarkable inhibitory action.
Be mainly used in driving away ascarid, pinworm, ancylostome, whipworm in body, treat various types of cysticercosis, as brain type, musculus cutaneus type, obvious effective rate is more than 80%, is used for the treatment of trichonematosis, and total effective rate reaches 100%, and curative effect is better than mebendazole.
At present, we mainly use albendazole tablet, but change along with cultivating structure, cultivate the vast of scale, make tradition rely on the mode manually gavaged can not adapt to high density scale livestock farming.The new mode of taking medicine to animal must be sought, reach the effect of lowering labor intensity.
And widely use along with albendazole, cause that a lot of boarding is infested has certain repellence, meanwhile, movable very active of distoma hepaticum in recent years, must on the basis of albendazole, additionally uses anti-liver sheet worm medicine as intramuscular injection sodium closantel injection.Invisible increase labor intensity, and to animal cause very large stress, cause growth retardation etc.For this reason, we must find out a kind of suitable medicament composing prescription and solve.
Summary of the invention
For solving above technical problem, the object of the present invention is to provide a kind of albendazole dispersible tablet for animals and preparation method thereof, the dispersible tablet prepared is convenient to animal and is taken, and growth of animal is normal, can not cause too drastic stress to animal.
The present invention seeks to realize like this:
A kind of albendazole dispersible tablet for animals, its key is: be made up of major ingredient, disintegrating agent, binding agent and adjuvant, and the ratio of weight and number of described major ingredient, disintegrating agent, binding agent and adjuvant is 40 ~ 85:3 ~ 10:5 ~ 15:5 ~ 25; Described major ingredient is made up of one or more in nitroclofene, the two dichloro of sulfur, ipecine, triclabendazole, metronidazole, praziquantel and albendazole, described adjuvant by micropowder silica gel, sodium lauryl sulphate one or both form.
Preferably, above-mentioned disintegrating agent is made up of carboxymethyl starch sodium (CMS-Na), low-substituted hydroxypropyl cellulose (L-HPC), crosslinked carboxymethyl fecula sodium (cCMC-Na) or cross linked polyvinyl pyrrolidone (PVPP).
Preferably, above-mentioned binding agent is made up of CMC, PVP (PVP) or hydroxypropyl emthylcellulose (HPMC).
Preferably, above-mentioned major ingredient is made up of albendazole, nitroclofene, and described disintegrating agent is CMS-Na, and described binding agent is PVP, described adjuvant is micropowder silica gel, and described albendazole, nitroclofene, CMS-Na, PVP and micropowder silica gel parts by weight adding proportion are 50:20:6:10:14.
A preparation method for albendazole dispersible tablet for animals, its key is to carry out according to the following steps:
(1) weigh: the ratio weighing major ingredient, disintegrating agent, binding agent and the stone that are 40 ~ 85:3 ~ 10:5 ~ 15:5 ~ 25 by ratio of weight and the number of copies;
(2) mill: symmetrical measured major ingredient carries out micronization processes, makes its microgranule be less than below 100mm for subsequent use;
(3) mix: the major ingredient of micronized process is mixed with disintegrating agent, binding agent and adjuvant, then carries out tabletting, obtain albendazole dispersible tablet.
Preferably, above-mentioned disintegrating agent is made up of carboxymethyl starch sodium (CMS-Na), low-substituted hydroxypropyl cellulose (L-HPC), crosslinked carboxymethyl fecula sodium (cCMC-Na) or cross linked polyvinyl pyrrolidone (PVPP).
Preferably, above-mentioned binding agent is made up of CMC, PVP (PVP) or hydroxypropyl emthylcellulose (HPMC).
Preferably, above-mentioned major ingredient is made up of albendazole, nitroclofene, and described disintegrating agent is CMS-Na, and described binding agent is PVP, described adjuvant is micropowder silica gel, and described albendazole, nitroclofene, CMS-Na, PVP and micropowder silica gel parts by weight adding proportion are 50:20:6:10:14.
Beneficial effect:
A kind of albendazole dispersible tablet for animals of the present invention and preparation method thereof, the dispersible tablet prepared is convenient to animal and is taken, and growth of animal is normal, can not cause too drastic stress to animal.
Accompanying drawing explanation
Nothing
Detailed description of the invention
Below in conjunction with embodiment, the invention will be further described.
Embodiment 1:
A kind of albendazole dispersible tablet for animals, is made up of major ingredient, disintegrating agent, binding agent and adjuvant,
Described major ingredient is made up of nitroclofene, sulfur two dichloro, ipecine, triclabendazole, metronidazole, praziquantel and albendazole.
Described adjuvant is made up of with arbitrary proportion micropowder silica gel, sodium lauryl sulphate.
Described disintegrating agent is made up of carboxymethyl starch sodium (CMS-Na).
Described binding agent is made up of CMC.
A preparation method for albendazole dispersible tablet for animals, carry out according to the following steps:
(1) weigh: the ratio weighing major ingredient, disintegrating agent, binding agent and the stone that are 40:3:5:5 by ratio of weight and the number of copies;
(2) mill: symmetrical measured major ingredient carries out micronization processes, makes its microgranule be less than below 100mm for subsequent use;
(3) mix: the major ingredient of micronized process is mixed with disintegrating agent, binding agent and adjuvant, then carries out tabletting, obtain albendazole dispersible tablet.
Embodiment 2:
A kind of albendazole dispersible tablet for animals, is made up of major ingredient, disintegrating agent, binding agent and adjuvant,
Described major ingredient is made up of albendazole, nitroclofene, described disintegrating agent is CMS-Na, described binding agent is PVP, and described adjuvant is micropowder silica gel, and described albendazole, nitroclofene, CMS-Na, PVP and micropowder silica gel parts by weight adding proportion are 50:20:6:10:14.
A preparation method for albendazole dispersible tablet for animals, carry out according to the following steps:
(1) weigh: weigh major ingredient, disintegrating agent, binding agent and stone by above-mentioned ratio of weight and number;
(2) mill: symmetrical measured major ingredient carries out micronization processes, makes its microgranule be less than below 100mm for subsequent use;
(3) mix: the major ingredient of micronized process is mixed with disintegrating agent, binding agent and adjuvant, then carries out tabletting, obtain albendazole dispersible tablet.
Embodiment 3:
A kind of albendazole dispersible tablet for animals, is made up of major ingredient, disintegrating agent, binding agent and adjuvant,
Described major ingredient is made up of the two dichloro of sulfur and albendazole,
Described adjuvant is made up of micropowder silica gel.
Described disintegrating agent is made up of low-substituted hydroxypropyl cellulose (L-HPC).
Described binding agent is made up of PVP (PVP).
A preparation method for albendazole dispersible tablet for animals, carry out according to the following steps:
(1) weigh: the ratio weighing major ingredient, disintegrating agent, binding agent and the stone that are 85:10:15:25 by ratio of weight and the number of copies;
(2) mill: symmetrical measured major ingredient carries out micronization processes, makes its microgranule be less than below 100mm for subsequent use;
(3) mix: the major ingredient of micronized process is mixed with disintegrating agent, binding agent and adjuvant, then carries out tabletting, obtain albendazole dispersible tablet.
Embodiment 3:
A kind of albendazole dispersible tablet for animals, is made up of major ingredient, disintegrating agent, binding agent and adjuvant,
Described major ingredient is made up of ipecine and albendazole,
Described adjuvant is made up of sodium lauryl sulphate.
Described disintegrating agent is made up of crosslinked carboxymethyl fecula sodium (cCMC-Na).
Described binding agent is made up of hydroxypropyl emthylcellulose (HPMC).
A preparation method for albendazole dispersible tablet for animals, carry out according to the following steps:
(1) weigh: the ratio weighing major ingredient, disintegrating agent, binding agent and the stone that are 70:8:13:20 by ratio of weight and the number of copies;
(2) mill: symmetrical measured major ingredient carries out micronization processes, makes its microgranule be less than below 100mm for subsequent use;
(3) mix: the major ingredient of micronized process is mixed with disintegrating agent, binding agent and adjuvant, then carries out tabletting, obtain albendazole dispersible tablet.
Embodiment 4:
A kind of albendazole dispersible tablet for animals, is made up of major ingredient, disintegrating agent, binding agent and adjuvant,
Described major ingredient is made up of triclabendazole and albendazole.
Described adjuvant is made up of micropowder silica gel.
Described disintegrating agent is made up of cross linked polyvinyl pyrrolidone (PVPP).
Described binding agent is made up of PVP (PVP).
A preparation method for albendazole dispersible tablet for animals, carry out according to the following steps:
(1) weigh: the ratio weighing major ingredient, disintegrating agent, binding agent and the stone that are 60:10:10:15 by ratio of weight and the number of copies;
(2) mill: symmetrical measured major ingredient carries out micronization processes, makes its microgranule be less than below 100mm for subsequent use;
(3) mix: the major ingredient of micronized process is mixed with disintegrating agent, binding agent and adjuvant, then carries out tabletting, obtain albendazole dispersible tablet.
Embodiment 5:
A kind of albendazole dispersible tablet for animals, is made up of major ingredient, disintegrating agent, binding agent and adjuvant,
Described major ingredient is made up of metronidazole and albendazole.
Described adjuvant is made up of micropowder silica gel.
Described disintegrating agent is made up of carboxymethyl starch sodium (CMS-Na).
Described binding agent is made up of PVP (PVP).
A preparation method for albendazole dispersible tablet for animals, carry out according to the following steps:
(1) weigh: the ratio weighing major ingredient, disintegrating agent, binding agent and the stone that are 50:4:6:7 by ratio of weight and the number of copies;
(2) mill: symmetrical measured major ingredient carries out micronization processes, makes its microgranule be less than below 100mm for subsequent use;
(3) mix: the major ingredient of micronized process is mixed with disintegrating agent, binding agent and adjuvant, then carries out tabletting, obtain albendazole dispersible tablet.
Embodiment 6:
A kind of albendazole dispersible tablet for animals, is made up of major ingredient, disintegrating agent, binding agent and adjuvant,
Described major ingredient by nitroclofene, tell praziquantel and albendazole forms.
Described adjuvant is made up of micropowder silica gel.
Described disintegrating agent is made up of carboxymethyl starch sodium (CMS-Na), low-substituted hydroxypropyl cellulose (L-HPC), crosslinked carboxymethyl fecula sodium (cCMC-Na) or cross linked polyvinyl pyrrolidone (PVPP).
Described binding agent is made up of CMC, PVP (PVP) or hydroxypropyl emthylcellulose (HPMC).
A preparation method for albendazole dispersible tablet for animals, carry out according to the following steps:
(1) weigh: the ratio weighing major ingredient, disintegrating agent, binding agent and the stone that are 85:5:8:18 by ratio of weight and the number of copies;
(4) mill: symmetrical measured major ingredient carries out micronization processes, makes its microgranule be less than below 100mm for subsequent use;
(5) mix: the major ingredient of micronized process is mixed with disintegrating agent, binding agent and adjuvant, then carries out tabletting, obtain albendazole dispersible tablet.
Finally it should be noted that, foregoing description is only the preferred embodiments of the present invention, adjuvant constituent described above preferred, and the composition combination do not embodied can carry out equivalent replacement.Those of ordinary skill in the art is under enlightenment of the present invention simultaneously, and under the prerequisite without prejudice to present inventive concept and claim, can make like multiple types and representing, such conversion all falls within protection scope of the present invention.
Claims (8)
1. an albendazole dispersible tablet for animals, is characterized in that: be made up of major ingredient, disintegrating agent, binding agent and adjuvant, and the ratio of weight and number of described major ingredient, disintegrating agent, binding agent and adjuvant is 40 ~ 85:3 ~ 10:5 ~ 15:5 ~ 25; Described major ingredient is made up of one or more in nitroclofene, the two dichloro of sulfur, ipecine, triclabendazole, metronidazole, praziquantel and albendazole, described adjuvant by micropowder silica gel, sodium lauryl sulphate one or both form.
2. albendazole dispersible tablet for animals according to claim 1, is characterized in that: described disintegrating agent is made up of carboxymethyl starch sodium (CMS-Na), low-substituted hydroxypropyl cellulose (L-HPC), crosslinked carboxymethyl fecula sodium (cCMC-Na) or cross linked polyvinyl pyrrolidone (PVPP).
3. albendazole dispersible tablet for animals according to claim 2, is characterized in that: described binding agent is made up of CMC, PVP (PVP) or hydroxypropyl emthylcellulose (HPMC).
4. albendazole dispersible tablet for animals according to claim 3, it is characterized in that: described major ingredient is made up of albendazole, nitroclofene, described disintegrating agent is CMS-Na, described binding agent is PVP, described adjuvant is micropowder silica gel, and described albendazole, nitroclofene, CMS-Na, PVP and micropowder silica gel parts by weight adding proportion are 50:20:6:10:14.
5. a preparation method for albendazole dispersible tablet for animals according to claim 1, is characterized in that carrying out according to the following steps:
(1) weigh: the ratio weighing major ingredient, disintegrating agent, binding agent and the stone that are 40 ~ 85:3 ~ 10:5 ~ 15:5 ~ 25 by ratio of weight and the number of copies;
(2) mill: symmetrical measured major ingredient carries out micronization processes, makes its microgranule be less than below 100mm for subsequent use;
(3) mix: the major ingredient of micronized process is mixed with disintegrating agent, binding agent and adjuvant, then carries out tabletting, obtain albendazole dispersible tablet.
6. the preparation method of albendazole dispersible tablet for animals according to claim 5, is characterized in that: described disintegrating agent is made up of carboxymethyl starch sodium (CMS-Na), low-substituted hydroxypropyl cellulose (L-HPC), crosslinked carboxymethyl fecula sodium (cCMC-Na) or cross linked polyvinyl pyrrolidone (PVPP).
7. the preparation method of albendazole dispersible tablet for animals according to claim 6, is characterized in that: described binding agent is made up of CMC, PVP (PVP) or hydroxypropyl emthylcellulose (HPMC).
8. the preparation method of albendazole dispersible tablet for animals according to claim 7, it is characterized in that: described major ingredient is made up of albendazole, nitroclofene, described disintegrating agent is CMS-Na, described binding agent is PVP, described adjuvant is micropowder silica gel, and described albendazole, nitroclofene, CMS-Na, PVP and micropowder silica gel parts by weight adding proportion are 50:20:6:10:14.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510666691.3A CN105213337A (en) | 2015-10-15 | 2015-10-15 | Albendazole dispersible tablet for animals and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510666691.3A CN105213337A (en) | 2015-10-15 | 2015-10-15 | Albendazole dispersible tablet for animals and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105213337A true CN105213337A (en) | 2016-01-06 |
Family
ID=54982859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510666691.3A Pending CN105213337A (en) | 2015-10-15 | 2015-10-15 | Albendazole dispersible tablet for animals and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105213337A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111067875A (en) * | 2020-01-16 | 2020-04-28 | 兰州大学 | Albendazole liquid-solid compressed tablet and preparation method thereof |
| CN111840234A (en) * | 2020-08-14 | 2020-10-30 | 瑞普（天津）生物药业有限公司 | Compound parasite expelling granule for livestock and preparation method thereof |
| CN115957192A (en) * | 2023-02-08 | 2023-04-14 | 成都乾坤动物药业股份有限公司 | Preparation method of nitrochlorophenol tablet and nitrochlorophenol compound tablet |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008075979A2 (en) * | 2006-12-21 | 2008-06-26 | Bomac Research Limited | Tablet formulation |
| CN102805736A (en) * | 2012-08-31 | 2012-12-05 | 宁夏启元国药有限公司 | Albendazol dispersible tablets and preparation method thereof |
| CN103520330A (en) * | 2013-10-15 | 2014-01-22 | 成都乾坤动物药业有限公司 | Veterinary dispersible tablet as well as preparation method and application thereof |
| CN103800354A (en) * | 2013-12-24 | 2014-05-21 | 沈阳伟嘉牧业技术有限公司 | Compound albendazole dry suspension and preparation method thereof |
| CN104274398A (en) * | 2013-07-04 | 2015-01-14 | 青岛康地恩动物药业有限公司 | Suspension containing albendazole, and preparation method thereof |
| CN104688683A (en) * | 2015-03-04 | 2015-06-10 | 西北农林科技大学 | Albendazole suspension and preparation method thereof |
-
2015
- 2015-10-15 CN CN201510666691.3A patent/CN105213337A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008075979A2 (en) * | 2006-12-21 | 2008-06-26 | Bomac Research Limited | Tablet formulation |
| CN102805736A (en) * | 2012-08-31 | 2012-12-05 | 宁夏启元国药有限公司 | Albendazol dispersible tablets and preparation method thereof |
| CN104274398A (en) * | 2013-07-04 | 2015-01-14 | 青岛康地恩动物药业有限公司 | Suspension containing albendazole, and preparation method thereof |
| CN103520330A (en) * | 2013-10-15 | 2014-01-22 | 成都乾坤动物药业有限公司 | Veterinary dispersible tablet as well as preparation method and application thereof |
| CN103800354A (en) * | 2013-12-24 | 2014-05-21 | 沈阳伟嘉牧业技术有限公司 | Compound albendazole dry suspension and preparation method thereof |
| CN104688683A (en) * | 2015-03-04 | 2015-06-10 | 西北农林科技大学 | Albendazole suspension and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111067875A (en) * | 2020-01-16 | 2020-04-28 | 兰州大学 | Albendazole liquid-solid compressed tablet and preparation method thereof |
| CN111067875B (en) * | 2020-01-16 | 2021-11-30 | 兰州大学 | Albendazole liquid-solid compressed tablet and preparation method thereof |
| CN111840234A (en) * | 2020-08-14 | 2020-10-30 | 瑞普（天津）生物药业有限公司 | Compound parasite expelling granule for livestock and preparation method thereof |
| CN115957192A (en) * | 2023-02-08 | 2023-04-14 | 成都乾坤动物药业股份有限公司 | Preparation method of nitrochlorophenol tablet and nitrochlorophenol compound tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101686962B (en) | Anthelmintic combination | |
| CN101700257B (en) | Pomegranate peel polyphenol antibiosis and antiphlogosis effervescent tablet as well as preparation method and application thereof | |
| MX2008016508A (en) | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders. | |
| GR1006569B (en) | Use of costic acid and other components derived from dittrichia viscosa plant and related sub-species thereof for fighting the varroa destructor's activity | |
| CN104688786B (en) | A kind of externally-applied medicinal composition and its preparation method and application | |
| CN105213337A (en) | Albendazole dispersible tablet for animals and preparation method thereof | |
| CN107551274A (en) | A kind of animal antifungal preparation and preparation method thereof | |
| Nyong et al. | In vitro and in vivo antimicrobial evaluation of alkaloidal extracts of Enantia chlorantha stem bark and their formulated ointments | |
| CN102935084A (en) | Compound ivermectin sustained release tablet and preparation method thereof | |
| CN102771486A (en) | Sterilization composition used for preventing and controlling rice sheath blight disease | |
| CN100393331C (en) | Composition for preventing and treating stomatosis and its preparing method | |
| CN107693532A (en) | Compound anti-parasitic preparation and preparation method thereof | |
| CN106983741B (en) | Application of the cyanoacrylate compound in the drug of preparation treatment people and animals' fungal infection disease | |
| CN104337822A (en) | Compound tablets containing mebendazole and dipterex and used for deworming on pets, and preparation method thereof | |
| CN105746519B (en) | A kind of composition pesticide containing fenoxanil and lentinan | |
| CN106614764A (en) | Fly killing agent containing macleaya cordata and cyromazine | |
| CN113209012A (en) | Avermectin transdermal solution and preparation method thereof | |
| EP2902024B1 (en) | Synergic composition of nitazoxanide and mebendazole, methods for the preparation thereof, and use of said composition for the treatment of human parasitosis | |
| CN110755533A (en) | Traditional Chinese medicine solution for treating skin diseases and preparation method and application thereof | |
| CN105106654A (en) | Method for preventing and treating sheep flock ecthyma | |
| CN106668171B (en) | Eucalyptus oil solution | |
| CN103550184A (en) | Metronidazole effervescent tablet | |
| CN103828841A (en) | Medicinal composition for preventing and controlling pebrine and application of medicinal composition | |
| AU2021103090A4 (en) | Medicinal Composition for Treating Animal Hydatid Disease and Preparation Method Thereof | |
| CN109700858A (en) | Rhizoma Polygoni suffulti is preparing the application in antifungal drug and its synergist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160106 |
|
| RJ01 | Rejection of invention patent application after publication |